PubMed · 15639052
Developments in glucocorticoid therapy.
Abstract
Recent evidence for a disease-modifying potential of low-dose glucocorticoids (GCs) in the treatment of rheumatoid arthritis has renewed the debate on the risk benefit ratio with this therapy. Two recent developments are described that might have a positive influence on these risk benefit ratios. One is the improvement in new GC compounds--designer GCs, alterations in bioactivity, and alterations in formulations. The other is a better understanding and management of the toxicity of GCs.
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
Johannes W J Bijlsma, Kenneth G Saag, Frank Buttgereit, José A P da Silva. 2005. Developments in glucocorticoid therapy.. https://doi.org/10.1016/j.rdc.2004.10.003
Cite the original work for its findings. Save a collection to share your selection of sources.